Advances in preclinical studies on borneol as an adjuvant for glioma

VernacularTitle:冰片辅助胶质瘤治疗的临床前研究进展
Author: Jing XIA ¹ ; Hang CHEN ¹ ; Jianming CHEN ¹ ; Xin WU ²
Author Information

1. School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China.
2. School of Pharmacy, Fujian University of Traditional Chinese Medicine, Fuzhou 350122, China;Shanghai Wei’er Laboratory, Shanghai 201712, China.
Keywords: glioma; borneol; chemotherapy; blood-brain barrier
From: Journal of Pharmaceutical Practice 2023;41(4):202-206
CountryChina
Language:Chinese
Abstract: Glioma is a common primary malignant brain tumor. At present, the main clinical treatment is surgical resection combined with radiotherapy and chemotherapy. Due to the selective permeability of the blood-brain barrier and the characteristics of multi-drug resistance of tumor cells, the therapeutic effect is not ideal. In recent years, studies have found that borneol could open the blood-brain barrier and promote the infiltration of chemotherapy drugs. When borneol is combined with or co-carried with chemotherapy drugs, chemotherapy drugs could target more glioma tissues and increase efficacy. The preclinical studies on the combination of borneol and chemotherapy drugs in recent years were reviewed in this article, in order to provide useful reference for the treatment of glioma.